{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:07:06Z","timestamp":1791662826316,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL14342"],"award-info":[{"award-number":["R01HL14342"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA180898"],"award-info":[{"award-number":["CA180898"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00277-020-04378-8","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T05:02:22Z","timestamp":1609650142000},"page":"1863-1870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies"],"prefix":"10.1007","volume":"100","author":[{"given":"Christian A.","family":"Gordillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa M.","family":"Delille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Assal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mapara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":false,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"4378_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.1983.1.6.359","volume":"1","author":"HM Lazarus","year":"1983","unstructured":"Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, Hurd D, Forman W, Gordon EM, Coccia P (1983) Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359\u2013367","journal-title":"J Clin Oncol"},{"key":"4378_CR2","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","volume":"118","author":"MT Cibeira","year":"2011","unstructured":"Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118:4346\u20134352","journal-title":"Blood"},{"key":"4378_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin\u2019s lymphoma. N Engl J Med 333:1995\u20131545","journal-title":"N Engl J Med"},{"key":"4378_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 341:1051\u20131054","journal-title":"Lancet"},{"key":"4378_CR5","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2007.14.7827","volume":"26","author":"HM Lazarus","year":"2008","unstructured":"Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP (2008) High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 26:2240\u20132243","journal-title":"J Clin Oncol"},{"key":"4378_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.bmt.1705384","volume":"37","author":"K Lilleby","year":"2006","unstructured":"Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplant. Bone Marrow Transplant 37:1031\u20131035","journal-title":"Bone Marrow Transplant"},{"key":"4378_CR7","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1200\/JCO.2007.13.6028","volume":"26","author":"N Blijlevens","year":"2008","unstructured":"Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S, European Blood and Marrow Transplantation Mucositis Advisory Group (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy\u2013European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26:1519\u20131525","journal-title":"J Clin Oncol"},{"key":"4378_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","volume":"38","author":"M Grazziutti","year":"2006","unstructured":"Grazziutti M, Dong L, Miceli M et al (2006) Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 38:501\u2013506","journal-title":"Bone Marrow Transplant"},{"key":"4378_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/bmt.2016.136","volume":"51","author":"K Sweiss","year":"2016","unstructured":"Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P (2016) Melphalan 200\u2009mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 51:1337\u20131341","journal-title":"Bone Marrow Transplant"},{"key":"4378_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1054\/bjoc.2001.1928","volume":"85","author":"B Sirohi","year":"2001","unstructured":"Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, Treleaven J (2001) Glomerular filtration rate prior to high-dose melphalan 200 mg\/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 85:325\u2013332","journal-title":"Br J Cancer"},{"key":"4378_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/10428194.2011.606942","volume":"53","author":"Q Bashir","year":"2012","unstructured":"Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH (2012) Feasibility of autologous hematopoietic stem cell transplant in patients aged \u226570 years with multiple myeloma. Leuk Lymphoma 53:118\u2013122","journal-title":"Leuk Lymphoma"},{"key":"4378_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","volume":"37","author":"E Jantunen","year":"2006","unstructured":"Jantunen E, Kuittinen T, Penttil\u00e4 K, Lehtonen P, Mahlam\u00e4ki E, Nousiainen T (2006) High-dose melphalan (200\u2009mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (\u226565 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37:917\u2013922","journal-title":"Bone Marrow Transplant"},{"key":"4378_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00280-003-0761-2","volume":"53","author":"P Mougenot","year":"2004","unstructured":"Mougenot P, Pinguet F, Fabbro M et al (2004) Population pharmokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol 53:503\u2013512","journal-title":"Cancer Chemother Pharmacol"},{"key":"4378_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","volume":"66","author":"PJ Selby","year":"1987","unstructured":"Selby PJ, McElwain TJ, Nandi AC et al (1987) Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55\u201362","journal-title":"Br J Haematol"},{"key":"4378_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","volume":"69","author":"CE Nath","year":"2010","unstructured":"Nath CE, Shaw PJ, Trotman J, Zeng L, Duffull SB, Hegarty G, McLachlan AJ, Gurney H, Kerridge I, Kwan YL, Presgrave P, Tiley C, Joshua D, Earl J (2010) Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol 69:484\u2013497","journal-title":"Br J Clin Pharmacol"},{"key":"4378_CR16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, de Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M (2010) Melphalan 200 mg\/m2 versus melphalan 100 mg\/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 115:1873\u20131879","journal-title":"Blood"},{"key":"4378_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"322","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 322:822\u2013824","journal-title":"Lancet"},{"key":"4378_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/bmt.2015.211","volume":"51","author":"WI Bensinger","year":"2016","unstructured":"Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK, Green DJ, Press OW, Lill M, Ifthikharuddin JJ, Vescio R, Holmberg LA, Phillips GL (2016) A randomized study of melphalan 200 mg\/m2 vs. 280 mg\/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 51:67\u201371","journal-title":"Bone Marrow Transplant"},{"key":"4378_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1408086","volume":"59","author":"E Malek","year":"2018","unstructured":"Malek E, Gupta V, Creger R et al (2018) Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma 59:1\u20138","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04378-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T06:06:16Z","timestamp":1623391576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04378-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4378"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04378-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The retrospective study was approved with waiver of informed consent by the Institutional Review Board at Columbia University Irving Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}